ALK and non-small cell lung carcinoma: Crizotinib received accelerated US Food and Drug Administration (FDA) approval for treatment of ALK-positive NSCLC based on an objective response rate of 60% and median PFS of 8–10 months in single-arm studies (16, 79, 83, 84).